Postoperative Adverse Events Following Concurrent Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence
International Urogynecology Journal · 07.11.2026
DOI: 10.1007/s00192-026-06968-y ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urogynecology Journal, online erschienen am 07.11.2026. Verfasst von K Marie Douglass und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urogynecology, Department of OB/GYN, Harbor-UCLA Medical Center, Torrance, CA, 90052, USA. KDouglass2@dhs.lacounty.gov. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Kaiser Permanente Division of Research.
Themen: Inkontinenz, Patientensicherheit
Abstract (Originalsprache)
INTRODUCTION AND HYPOTHESIS: For mixed urinary incontinence, concomitant midurethral sling (MUS) and onabotulinumtoxinA (Botox® (BTX-A)) can be considered, but data regarding safety are sparse. Adverse event rates following combined MUS + BTX-A are hypothesized to be similar to those following MUS alone. METHODS: This was a retrospective matched cohort study comparing adverse events in patients with mixed incontinence undergoing MUS (n = 200) versus combined MUS + BTX-A (n = 100) between January 1, 2011, and March 31, 2024. The primary outcome was culture proven urinary tract infection (UTI) at 3 and 6 months. Secondary outcomes included any UTI (culture proven or empirically treated), urinary retention, and postoperative overactive bladder (OAB) treatment. Logistic regression was used to assess the impact of baseline variables on outcomes. RESULTS: Patients undergoing concurrent MUS + BTX-A were more likely to have prior stress incontinence surgery, OAB treatment, and postoperative prophylactic antibiotic use. Culture-proven UTI occurred more frequently in the MUS + BTX-A group at 3 months (23.0% vs 12.5%) and 6 months (25.0% vs 15.0%) on unadjusted analysis. After adjustment for measured covariates, the association was attenuated and not statistically significant at 3 months (adjusted OR 1.60, 95% CI 0.78-3.30) or 6 months (adjusted OR 1.47, 95% CI 0.75-2.91). Rates of retention-related events and subsequent OAB treatment were similar between groups. CONCLUSIONS: Concurrent MUS + BTX-A was associated with higher crude of culture-proven UTI, although adjusted analyses did not demonstrate a statistically significant association. Larger studies are needed to better define the safety of concurrent treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urogynecology, Department of OB/GYN, Harbor-UCLA Medical Center, Torrance, CA, 90052, USA. KDouglass2@dhs.lacounty.gov.
- Division of Urogynecology, Department of OB/GYN, University of Chicago-Endeavor Health, Evanston, IL, 60201, USA.
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
- Division of Urogynecology, Department of OB/GYN, Kaiser Permanente Downey Medical Center, Downey, CA, 90239, USA.
Förderung
- Kaiser Permanente Division of Research
Zitieren
APA
Douglass, K. M., Crawford, K., Zhang, J., Barton, L., Lewis, S., Tovar, S., & Jakus-Waldman, S. (2026). Postoperative Adverse Events Following Concurrent Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence. International Urogynecology Journal. https://doi.org/10.1007/s00192-026-06968-y
Vancouver
Douglass KM, Crawford K, Zhang J, Barton L, Lewis S, Tovar S, et al. Postoperative Adverse Events Following Concurrent Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence. International Urogynecology Journal. 2026. doi:10.1007/s00192-026-06968-y
BibTeX
@article{Douglass2026,
author = {Douglass, K Marie and Crawford, Kaitlin and Zhang, Jing and Barton, Lee and Lewis, Sierra and Tovar, Stephanie and Jakus-Waldman, Sharon},
title = {Postoperative Adverse Events Following Concurrent Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence},
journal = {International Urogynecology Journal},
year = {2026},
doi = {10.1007/s00192-026-06968-y}
}
EUVIMED